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A B S T R A C T
This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows:
Primary objective
• To assess the evidence on the accuracy of CGMS in detecting abnormalities of glycaemic control in children and adults with CF.
B A C K G R O U N D
Cystic fibrosis (CF) is the most common autosomal recessive in-
herited condition in white populations; with a genetic carrier rate
of 1 in 25 people, it affects around 1 in 2500 newborns in the
UK (Farrell 2008; Ratjen 2003). It mainly affects the lungs, and
the main cause of death is respiratory failure. This condition also
affects the pancreas, particularly the β-cells, leading to cystic fi-
brosis-related diabetes (CFRD) due to insulin deficiency.
As the survival of people with CF has been improving over the
last few decades, there has been a noticeable increase in the re-
ported prevalence of CFRD. Almost half of adults with CF aged
20 years and older are estimated to have CFRD; the prevalence
of CFRD and the mortality rate in adults with CFRD has been
noted to increase with age (Lewis 2015). Increased awareness and
screening for CFRD has also contributed to the increase in the
reported prevalence of CFRD. Continuous glucose monitoring
systems (CGMS) may help especially in the early diagnosis of glu-
cose abnormalities in children with CF, potentially allowing earlier
treatment of CFRD and better clinical outcomes.
Target condition being diagnosed
The onset of CFRD is insidious, and classical symptoms of dia-
betes may be absent. People with CF are more likely to present
with CFRD when there is an increased insulin resistance such as
during lung infections or while using steroids (Moran 2014). Mi-
crovascular complications including kidney disease and retinopa-
thy, resulting from prolonged periods of hyperglycaemia may be
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less common in CFRD compared to the non-CF diabetic pop-
ulation (Landers 1997; Schwarzenberg 2007). However, CFRD
is associated with an accelerated decline in lung function, a re-
duction in body mass index (BMI) (Lanng 1994; Moran 2010)
and ultimately in worse survival. With longer survival in people
with CF, there may be an increased prevalence of complications of
CFRD, which can impact on survival and the quality of life (Koch
2001; Lewis 2015).
When people with CF are otherwise clinically stable, the diagnosis
of CFRD is made as per standard American Diabetic Association
(ADA) criteria (ADA 2016). Therefore, CFRD is diagnosed if on
the oral glucose tolerance test (OGTT), the two-hour blood glu-
cose is high (at least 11.1 mmol/L); there is a high fasting glu-
cose of at least 7 mmol/L; HbA1C is increased at least 6.5%; or
if there is a random blood glucose level of at least 11.1 mmol/L
(random blood glucose is different to fasting blood glucose and
is measured at any time of the day) with symptoms suggestive of
hyperglycaemia or hyperglycaemic crisis. In people with CF who
are acutely ill (individuals on intravenous antibiotics or glucocor-
ticoids), the diagnosis of CFRD is made when the fasting plasma
glucose levels are more than 7.0 mmol/ L or two-hour post-pran-
dial plasma glucose levelsmore than 11.1 mmol/L persist for more
than 48 hours (ADA 2016).
Index test(s)
Since 2000, CGMS have been available for managing diabetes
mellitus (Gross 2000). They measure interstitial fluid glucose lev-
els to provide semi-continuous information, which identifies fluc-
tuations that cannot be identified with intermittent blood sugar
monitoring (Langendam 2012).
Since the introduction of CGMS, there has been a significant im-
provement in the accuracy, user-friendliness and data analysis soft-
ware along with a reduction in the size and cost of these devices
(Damiano 2014; Pleus 2015). Most systems use a needle sensor,
inserted under the skin, but non-invasive systems are also avail-
able. These systems measure the glucose concentration in the in-
terstitial fluid that is triggered by applying a local electric current
(iontophoresis) (Chase 2005). Currently, CGMS are available to
individuals who use an electrochemical approach to glucose mea-
surement. Many different approaches like micro-dialysis and fully
implantable sensors have previously been tried with varying suc-
cess rates (Garg 2004; Vaddiraju 2010; Valgimigli 2010).
Data from CGMS are presented by ambulatory glucose profile
(AGP), this report includes a visual display of the glucose profile
over the entire time duration of testing. As there are different
CGMS currently used, there are variations in test methods. One
parameter often used to characterise the analytical performance of
CGMS is the mean absolute relative difference (MARD) between
the CGMS readings (sometimes themedian value is also used) and
the values measured at the same time using a reference system (e.g.
blood glucose levels). This parameter can be used to summarise
results (Kropff 2015).
It is possible to useCGMScontinuously or intermittently, but they
are typically used over a period of three to seven days when clinical
concerns regarding blood glucose control are raised, or to fine tune
insulin treatment regimens. Although CGMS have been shown to
have good repeatability and reliability (O’Riordan 2009), there is
limited evidence on the accuracy of CGMS to diagnose CFRD.
There are no agreed standard criteria for diagnosing CFRD using
CGMS. As the ADA criteria are the clinical reference standard for
CFRD (ADA 2016), the diagnostic criteria for a positive CGMS
should be consistent with the above. The criteria for test-positivity
for CFRD using CGMS in this review are a fasting glucose of
greater than 7.0 mmol/L or a random glucose level greater than
11.1 mmol/L on more than one occasion.
Clinical pathway
People (both children and adults) with CF should be investigated
for CFRD in any of the following situations (ADA 2016).
• Annual review for all children over 10 years of age
• Clinical concerns
• Finding of high blood glucose levels in any individual
• High glycated haemoglobin (HbA1c) greater than 6.5%
(International Federation of Clinical Chemistry - IFCC HbA1c
over 48 mmol/mol)
• Symptoms of hyperglycaemia
• Unexplained weight loss
• Unexplained reduction in lung function
• Prior to starting corticosteroids, overnight feeds, or before
major surgery
The diagnosis of CFRD is made as per standard ADA criteria
(ADA2016) (see Target condition being diagnosed).Misdiagnosis
of CFRD, both false positive and false negative, can occur.Missing
a diagnosis or a delayed diagnosis can lead to worsening lung
function and nutritional status, thereby having a negative impact
on the clinical status and quality of life of people with CF.
Alternative test(s)
The ADA criteria recommend that CFRD should be diagnosed
using the two-hour 75 g (1.75 g/kg) OGTT (ADA 2016). The
OGTT also detects individuals with impaired glucose tolerance.
It is important to note that, although the results of OGTT are not
always reproducible and can vary over time (Ko 1998; Mueller-
Brandes 2005; Sterescu 2010), it continues to be recommended
in most consensus statements.
Using HbA1c to diagnose CFRD has been shown to be unreli-
able because it can be falsely low due to increased red blood cell
turnover (Dobson 2004; Lanng 1995). A high HbA1c suggests
hyperglycaemia, but a normal HbA1c does not exclude it.
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People with CF can have CFRD despite their fasting glucose lev-
els or their random glucose levels being normal; the above tests
have both low sensitivity and specificity for diagnosis of CFRD
(Godbout 2008; Yung 1999).
Rationale
Due to improved survival of people with CF and increased screen-
ing for CFRD, the reported prevalence of CFRD is increasing
(Lewis 2015). Earlier diagnosis of CFRD may help in the early
initiation of treatment and better control of the blood sugars to
improve clinical outcomes. Currently, CFRD is diagnosed as per
the ADA criteria which include clinical symptoms in combination
with OGTT, HBA1C and plasma glucose levels (ADA 2016).
In people with CF with both normal and altered glucose tolerance
at OGTT, episodes of hyperglycaemia have been picked up on
CGMS (Schiaffini 2010). The use of CGMS may therefore help
to diagnose glucose abnormalities earlier in children with CF (
Soliman 2014); however, there is limited evidence on its accuracy
in people with CF.
The clinical utility of CGMS in predicting outcomes in CF is also
unknown. Interstitial fluid blood glucose levels greater than 7.8
mmol/L on CGMS for more than 4.5% of the time have been
noted to have an association with a decline in lung function and
weight over the preceding year (Hameed 2010).
O B J E C T I V E S
Primary objective
• To assess the evidence on the accuracy of CGMS in
detecting abnormalities of glycaemic control in children and
adults with CF.
Secondary objectives
• To investigate the potential causes of heterogeneity
[including age, severity of lung disease, glycaemic control,
symptomatic and asymptomatic individuals, timing of testing
(during stable disease or an infective exacerbation) and the type
of CGMS] and their influence on the diagnostic accuracy of
CGMS in CFRD.
• To identify gaps in the evidence and identify areas where
further research is required.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include cross-sectional studies and prospective cohort
studies that compare CGMS against the reference standard in the
diagnosis of CFRD as outlined by the ADA criteria (ADA 2016).
We will also include randomised comparisons of tests in which
all participants have been cross-classified with a reference stan-
dard. We will exclude case-control studies, case reports, and stud-
ies where CGMS is performed retrospectively after an abnormal
OGTT. We also plan to exclude systematic reviews, although we
will extract any relevant primary studies.
Participants
Wewill include studies involvingpeople (both children and adults)
with CF in whom CFRD is suspected or who are being routinely
screened for CFRD. The diagnosis of CF is confirmed by the
presence of two disease-causing mutations, or by a combination
of positive sweat test and associated clinical features of CF.
Index tests
The index test for this review is CGMS.
Target conditions
The target condition is CFRD.
Reference standards
The clinical reference standard is the diagnosis of CFRD as out-
lined by the ADA criteria (see Target condition being diagnosed).
Search methods for identification of studies
We will search for all relevant published and unpublished trials
without restrictions on language, year or publication status.
Electronic searches
Wewill identify relevant studies from theCochraneCystic Fibrosis
and Genetic Disorders Group’s Cystic Fibrosis Register using the
term: cystic fibrosis-related diabetes [CFRD] and impaired glucose
tolerance [IGT].
The Cystic Fibrosis Trials Register has been compiled from elec-
tronic searches of the Cochrane Central Register of Controlled
Trials (CENTRAL) (updated each new issue of the Cochrane Li-
brary), weekly searches ofMEDLINE, a search of Embase to 1995
and the prospective Handsearching of two journals - Pediatric Pul-
monology and the Journal of Cystic Fibrosis. Unpublished work has
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been identified by searching the abstract books of three major
cystic fibrosis conferences: the International Cystic Fibrosis Con-
ference; the European Cystic Fibrosis Conference and the North
American Cystic Fibrosis Conference. For full details of all search-
ing activities for the register, please see the relevant sections of the
Cystic Fibrosis and Genetic Disorders Group website.
We will also search the following databases, trials registries and
resources:
• Cochrane Central Register of Controlled Trials
(CENTRAL; all years) in the Cochrane Library
www.cochranelibrary.com/;
• MEDLINE Healthcare Databases Advanced Search
(HDAS) (hdas.nice.org.uk/ 1946 to present);
• Embase Healthcare Databases Advanced Search (HDAS) (
hdas.nice.org.uk/ 1974 to present);
• ISRCTN registry (www.isrctn.org);
• US National Institutes of Health Ongoing Trials Register
Clinicaltrials.gov (www.clinicaltrials.gov);
• World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP) (apps.who.int/trialsearch).
See the appendices for the full search strategies (Appendix 1;
Appendix 2; Appendix 3).
Searching other resources
Wewill review the reference lists of all included articles and relevant
systematic reviews to identify any additional studies.
We will hand search two highly-relevant journals - Pediatric Pul-
monology and the Journal of Cystic Fibrosis (last five years). We will
also hand search the abstract books of the EuropeanCystic Fibrosis
Conference, the North American Cystic Fibrosis Conference and
the major diabetology meetings (Diabetes UK, European Associ-
ation for the Study of Diabetes, the ADA, and the International
Society for Pediatric and Adolescent Diabetes) (last five years).
Data collection and analysis
Selection of studies
Two authors (MA, RF) will independently apply the selection
criteria to determine the studies to be included in the review. We
will perform the screening of title and abstracts and follow this by
screening of full text articles.We will resolve differences in opinion
through discussion, or if needed, by a third review author. We will
use the kappa statistic to measure the inter-rater agreement for
study selection (Cohen 1960), anddetail reasons for any exclusions
in a flow diagram.
Data extraction and management
We shall construct customised data extraction forms to facilitate
independent data extraction. Two authors (MA, RF) will pilot this
form using five initial studies and refine it, if and where necessary.
In the case of any disagreements on the suitability of a study or
its risk of bias, the authors plan to reach a consensus through
discussion. In studies where the required information is missing,
the review authors aim to contact the trial authors to seek this
additional information.
We shall extract the following information for each study.
• Study information: first author, year of publication,
country, language, objectives, inclusion and exclusion criteria
and study design.
• Study participants: study population, included participants,
age, incidence of acute pulmonary exacerbations, BMI, lung
function, new isolation of bacterial pathogens.
• Information on the index test and reference standard: test
methods, positivity threshold(s) used including how serial
measurements were combined to inform the diagnosis, number
of test failures and inconclusive results (and reasons for them),
the number of measurements and the time-points at which
measurements were taken and any adverse effects including
infection, bleeding, irritation of skin, allergy to taping, pain and
any issues on insertion. For each measurement recorded from the
index test, we will note whether a comparative reference standard
measurement was available.
• Number of true positives, true negatives, false positives and
false negatives - we plan to use the above information to
construct a 2 x 2 table for each measurement time-point. Where
necessary and feasible, we will back-calculate this information
from reported sensitivity, specificity and prevalence estimates.
Assessment of methodological quality
We will use the QUADAS-2 (quality assessment of diagnostic ac-
curacy studies) tool to assess the risk of bias and concerns regarding
applicability for all included studies. We will assess the risk of bias
in each of the four key domains (participant selection, index test,
reference standard, flow and timing) using the signalling questions
(Whiting 2011); we will also assess any concerns regarding appli-
cability in the first three domains.
We will produce graphs indicating the risk of bias in the Review
Manager (RevMan) software and will present the overall scores
for each domain (RevMan 2014). Two review authors (MA, RF)
will independently assess all the included trials. We aim to resolve
any potential disagreements by discussion or, where necessary, by
a third review author.
We have detailed the components and signalling questions associ-
ated with each of the domains of the QUADAS-2 (Appendix 4).
Statistical analysis and data synthesis
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The diagnosis of CFRD is made as per standard ADA criteria (See
Target condition being diagnosed). There are no agreed standard
criteria for diagnosingCFRDonCGMS.As theADAcriteria is the
clinical reference standard for CFRD (ADA 2016), the diagnostic
criteria for a positive CGMS should be consistent with the above.
The criteria for test-positivity for CFRD using CGMS in this
review are a fasting glucose of greater than7.0mmol/Lor a random
glucose level greater than11.1mmol/Lonmore thanone occasion.
We shall conduct the analyses in line with chapter 10 of the
Cochrane Handbook for Systematic Reviews of Diagnostic Test Accu-
racy (Macaskill 2010).
We shall use descriptive statistics to present a summary of the data
extracted from each included study. The tables will report the par-
ticipant sample size, study design and the methods or devices that
are used to monitor continuous glucose levels. In addition, we will
summarise the number of measurements and associated timings
of measurements within each study. We shall extract binary diag-
nostic accuracy data from all included trials as 2 x 2 tables. Where
we base the 2 x 2 tables on data from serial measurements, we will
summarise themethods used to interpret serial measurements, e.g.
the average of four serial measurements.
We expect that the positivity thresholds applied for the index test
will vary across the included studies. In this case, we shall conduct
the meta-analysis across all studies using the hierarchical summary
receiver operating characteristic (HSROC) model (Rutter 2001)
to estimate a summary curve using the NLMIXED procedure in
SAS (SAS 2011). If different methods for interpreting serial mea-
surements have been employed, we will only include studies us-
ing common methodology for meta-analysis. This may result in a
number of subgroup meta-analyses. If there are a sufficient num-
ber of studies that report at common positivity thresholds, we will
conduct subgroup meta-analyses using the bivariate method to
provide pooled sensitivity and specificity estimates for each thresh-
old (Reitsma 2005).
We will use RevMan to produce forest plots showing the variabil-
ity of sensitivity and specificity across the included studies with
corresponding 95% confidence intervals (CIs). We aim to break
down the forest plots into subgroups where possible and necessary,
e.g. for different positivity thresholds (Macaskill 2010).
Investigations of heterogeneity
We will initially assess for heterogeneity by visually examining the
forest plots of sensitivities and specificities and the ROC (receiver
operating characteristic) plots.
There are a number of possible factors that may account for be-
tween-study differences in the accuracy of CGMS. Where com-
mon differences in test methods (index test or reference standard)
or study participants are evident, we will explore whether these
factors result in notable differences in accuracy. In particular, we
envisage that the following participant factors are likely to influ-
ence the accuracy of CGMS:
• age (all ages to be included);
• asymptomatic versus symptomatic individuals;
• severity of lung disease - mild lung disease (forced expiratory
volume in one second (FEV1) of 80% to 100% predicted) versus
moderate disease (FEV1 between 40% and 80% predicted)
versus severe disease (FEV1 less than 40% predicted);
• glycaemic control - HbA1c less than 7% versus HbA1c 7%
to 8% versus HbA1c greater than 8%; and
• timing of CGMS - CGMS performed when participant is
clinically stable versus during an episode of pulmonary
exacerbation;
• type of CGMS.
Where the report breaks down the 2 x 2 data, or if a subset of the in-
cluded studies is limited to a particular subgroup (e.g. adolescents),
we will carry out subgroup meta-analyses to explore whether there
are notable differences in the pooled estimates of sensitivity and
specificity. If sufficient information for a particular factor is avail-
able across all studies, we will perform meta-regression which in-
volves adding the potential source(s) of heterogeneity as a covari-
ate to the meta-analysis model.We will use the Metadas Macro in
SAS to perform this analysis.
Sensitivity analyses
If necessary and appropriate, we shall perform sensitivity analyses
excluding studies that are at a high risk of bias for at least one
domain of theQUADAS-2 tool (see Assessment ofmethodological
quality).
Assessment of reporting bias
There is no consensus on the ideal methodology to identify re-
porting bias in reviews of diagnostic test accuracy. We shall not
be using existing analytical tools such as funnel plots as there is
lack of evidence of their usefulness in these reviews (Deeks 2005).
We shall perform a comprehensive search for all eligible studies
(Search methods for identification of studies).
Summary of findings tables
We will prepare a summary of findings table, this shall include the
review question, any limitations noted while assessing the risk of
bias and applicability, or excessive heterogeneity and the estimates
of the accuracy of CGMS.
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A P P E N D I C E S
Appendix 1. Search strategies for MEDLINE and Embase
MEDLINE and Embase searches will be run on the NICE Evidence Healthcare Databases Advanced Search (HDAS) Platform. Some
of the search lines have been specially adapted for this database - where MEDLINE defaults to five characters after the star in truncation
unless a larger number is specified. So in terms where a larger number of characters was considered to be possible we used *9. HDAS
will not search two truncated terms in inverted commas for phrase searching, so we have used adj as an alternative.
MEDLINE Search
# Search term
1 exp “CYSTIC FIBROSIS”/
2 (cystic* ADJ5 fibro*).af
3 (Mucoviscido*).af
4 (fibrocyst* ADJ5 pancrea*9).af
5 (1 OR 2 OR 3 OR 4)
6 exp “DIABETES MELLITUS”/
7 (diabet*).af
8 (glucose).af
9 (hyperglyc*9).af
10 (hypoglyc*9).af
11 (igt).af
12 (ogtt).af
13 (insulin*).af
14 (postprandial*).af
15 (“post prandial*”).af
16 exp “GLUCOSE TOLERANCE TEST”/
17 exp “GLUCOSE INTOLERANCE”/
18 exp HYPERGLYCEMIA/
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(Continued)
19 exp GLUCOSE/
20 exp BLOOD GLUCOSE/
21 exp HYPOGLYCEMIA/
22 exp INSULIN/
23 (“after food”).af
24 (“after eating”).af
25 exp POSTPRANDIAL PERIOD/
26 (7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 2O OR 21
OR 22 OR 23 OR 24 OR 25)
27 (5 AND 26)
28 (cfrd*).af
29 (26 OR 28)
30 exp “BLOOD GLUCOSE SELF-MONITORING”/
31 (glucose ADJ5 monitor*).af
32 (sugar* ADJ5 monitor*).af
33 (hba* ADJ5 monitor*).af
34 (hba* ADJ5 sensor*).af
35 (glucose ADJ5 sensor*).af
36 (sugar* ADJ5 sensor*).af
37 (cgm OR cgms).af
38 (continuous*9 ADJ5 monitor*).af
39 (glucowatch*).af
40 (navigator*).af
41 (medtronic).af
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(Continued)
42 (glucosemeter*).af
43 (guardian*).af
44 (dexcom).af
45 (minimed*).af
46 (enlite).af
47 (animas).af
48 (vibe).af
49 (30 OR 31 OR 32 OR 33 OR 34 OR 35 OR 36 OR 37 OR 40 OR 41 or 42 or 43 or 44 or 45 or 46 or 47
or 48)
50 (49 AND 29)
Embase Search
# Search term
1 exp “CYSTIC FIBROSIS”/
2 (cystic* ADJ10 fibro*).af
3 (Mucoviscido*).af
4 (fibrocyst* ADJ10 pancrea*9).af
5 (1 OR 2 OR 3 OR 4)
6 exp “DIABETES MELLITUS”/
7 exp “ORAL GLUCOSE TOLERANCE TEST”/
8 exp “GLUCOSE BLOOD LEVEL”/
9 exp “ORAL GLUCOSE TOLERANCE TEST”/
10 exp GLUCOSE/
11 exp INSULIN/
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(Continued)
12 exp “IMPAIRED GLUCOSE TOLERANCE”/
13 exp HYPERGLYCEMIA/
14 exp HYPOGLYCEMIA/
15 exp “POSTPRANDIAL STATE”/
16 (diabet*).af
17 (glucose).af
18 (hyperglyc*9).af
19 (hypoglyc*9).af
20 (igt).af
21 (ogtt).af
22 (insulin*).af
23 (postprandial*).af
24 (“post prandial*”).af
25 (“after food”).af
26 (“after eating”).af
27 (6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21
OR 22 OR 23 OR 24 OR 25 OR 26)
28 (cfrd*).af
29 (5 AND 27)
30 exp “BLOOD GLUCOSE SELF-MONITORING”/
31 (glucose ADJ5 monitor*).af
32 (sugar* ADJ5 monitor*).af
33 (hba* ADJ5 monitor*).af
34 (hba* ADJ5 sensor*).af
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(Continued)
35 (glucose ADJ5 sensor*).af
36 (sugar* ADJ5 sensor*).af
37 (cgm OR cgms).af
38 (continuous*9 ADJ5 monitor*).af
39 (glucowatch*).af
40 (navigator*).af
41 (medtronic).af
42 (glucosemeter*).af
43 (guardian*).af
44 (dexcom).af
45 (minimed*).af
46 (enlite).af
47 (animas).af
48 (vibe).af
49 (30 OR 31 OR 32 OR 33 OR 34 OR 35 OR 36 OR 37 OR 38 OR 39 OR 40 OR 41 OR 42 OR 43 OR 44 OR
45 OR 46 OR 47 OR 48)
50 (28 AND 29)
51 (49 AND 50)
Appendix 2. Search strategy for CENTRAL
CENTRAL search
# Search term
1 MeSH descriptor: [Cystic Fibrosis] explode all trees
2 cystic* near/5 fibro*
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(Continued)
3 mucoviscido*
4 fibrocyst* near/5 pancrea*
5 #1 or #2 or #3 or #4
6 MeSH descriptor: [Diabetes Mellitus] explode all trees
7 MeSH descriptor: [Glucose Tolerance Test] explode all trees
8 MeSH descriptor: [Glucose Intolerance] explode all trees
9 MeSH descriptor: [Hyperglycemia] explode all trees
10 MeSH descriptor: [Blood Glucose] explode all trees
11 MeSH descriptor: [Glucose] explode all trees
12 MeSH descriptor: [Hypoglycemia] explode all trees
13 MeSH descriptor: [Insulin] explode all trees
14 MeSH descriptor: [Postprandial Period] explode all trees
15 diabet* or glucose* or hyperglyc* or hypoglyc* or igt or ogtt or insulin* or postprandial*
16 “post prandial*”
17 “after food”
18 “after eating”
19 #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18
20 #5 and #19
21 cfrd
22 #20 or #21
23 MeSH descriptor: [Blood Glucose Self-Monitoring] explode all trees
24 glucose near/5 monitor*
25 sugar* near/5 monitor*
26 hba* near/5 sensor*
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(Continued)
27 glucose near/5 sensor*
28 sugar* near/5 sensor*
29 cgm or cgms
30 continuous* near/5 monitor*
31 glucowatch* or navigator* or medtronic or glucosemeter* or guardian* or dexcom
32 minimed* or enlit or animas or vibe
33 #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32
24 #22 and #33
Appendix 3. Search methods - electronic searching
Database/ Resource Strategy
ISRCTN registry (”cystic fibrosis“) AND(glucoseORdiabet*OR insulinOR sugar*
OR hba1C OR glucowatch OR postprandial* OR cgm OR cgms
OR navigator* OR hyperglyc* OR hypogly* OR igt OR ogtt OR
”post prandial*“ OR ”after food“OR ”after eating“ ORMedtronic
OR glucosemeter OR guardian* OR dexcom OR minimed* OR
enlite OR animas OR vibe) OR (”mucoviscido*) AND (glucose
ORdiabet* OR insulin OR sugar* ORhba1COR glucowatch OR
postprandial* OR cgm OR cgms OR navigator* OR hyperglyc*
ORhypogly*OR igtORogttOR “post prandial*”OR “after food”
OR “after eating” ORMedtronic OR glucosemeter OR guardian*
OR dexcom OR minimed* OR enlite OR animas OR vibe) OR
(“fibrocyst* pancrea*”) AND (glucose OR diabet* OR insulin OR
sugar* OR hba1C OR glucowatch OR postprandial* OR cgm
OR cgms OR navigator* OR hyperglyc* OR hypogly* OR igt
OR ogtt OR “post prandial*” OR “after food” OR “after eating”
OR Medtronic OR glucosemeter OR guardian* OR dexcom OR
minimed* OR enlite OR animas OR vibe)
ClinicalTrials.gov (“cystic fibrosis” OR mucoviscido* OR “fibrocyst* pancrea*”)
AND (glucose OR diabet* OR insulin OR sugar* OR hba1C OR
glucowatch OR postprandial* OR cgm OR cgms OR navigator*
OR hyperglyc* OR hypogly* OR igt OR ogtt OR “post prandial*”
OR “after food” OR “after eating” ORMedtronic OR glucoseme-
ter OR guardian* OR dexcom OR minimed* OR enlite OR ani-
mas OR vibe)
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(Continued)
WHO International Clinical Trials Registry Platform (ICTRP) (“cystic fibrosis” OR mucoviscido* OR “fibrocyst* pancrea*”)
AND (glucose OR diabet* OR insulin OR sugar* OR hba1C OR
glucowatch OR postprandial* OR cgm OR cgms OR navigator*
OR hyperglyc* OR hypogly* OR igt OR ogtt OR “post prandial*”
OR “after food” OR “after eating” ORMedtronic OR glucoseme-
ter OR guardian* OR dexcom OR minimed* OR enlite OR ani-
mas OR vibe)
Appendix 4. Assessment of methodological quality : Quadas 2 Criteria
Domain 1: Participant selection 2: Index Test 3: Reference Standard 4: Flow and timing
Signalling questions
and criteria
Signalling question 1:Was
a consecutive or random
sample of participants en-
rolled?
• Yes: if the study
clearly stated that
enrolment was
consecutive or random.
• No: if the above
condition was not met.
• Unclear:
insufficient information
available to answer yes
or no.
Signalling ques-
tion 1: Were the index test
results interpreted without
knowledge of the results of
the reference standard?
• Yes: if the study
states that CGMS was
performed prior to
assessment of ADA
criteria or that the
interpretation of the
CGMS was blinded to
the results of the
reference standard.
• No: if the CGMS
results were interpreted
with the knowledge of
the results of the
reference standard.
• Unclear:
insufficient information
available to answer “yes”
or “no”.
Sig-
nalling question 1: Is the
reference standard likely to
correctly classify the target
condition?
• Yes: if the reference
standard used was
consistent with the
ADA criteria in the
diagnosis of CFRD.
• No: if the above
condition is not met.
• Unclear:
insufficient information
available to answer “yes”
or “no”
Signalling question 1:Was
there an appropriate in-
terval between index test
(s) and reference standard?
• Yes: if the CGMS
was performed within
three months of the
reference test.
• No: if the reference
test for all participants
was performed more
than three months after
the CGMS.
• Unclear: if not
reported or cannot be
determined
Signalling question 2:Did
the study describe clear in-
clusion criteria for par-
ticipants with suspected
CFRD?
• Yes: specific
inclusion criteria were
described in the study
methodology.
Signalling question 2: If a
threshold was used, was it
pre-specified?
• Yes: thresholds
were used and clearly
defined and pre-
specified.
• No: if the above
conditions were not
Signalling questions 2:
Were the reference stan-
dard results interpreted
without knowledge of the
results of the index test?
• Yes: if the reference
standard results were
interpreted without the
knowledge of CGMS
Signalling question 2:Did
all participants receive a
reference standard?
• Yes: if all
participants had
investigations to
diagnose CFRD
according to the ADA
criteria.
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(Continued)
• No: no inclusion
criteria described.
• Unclear:
insufficient information
available
met.
• Unclear:
insufficient information
available to answer “yes”
or “no”.
results.
• No: if the above
condition is not met.
• Unclear:
insufficient information
available to answer “yes”
or “no”
• No: if the above
condition is not met.
• Unclear:
insufficient information
available to answer “yes”
or “no”.
Signalling question 3:Did
the study avoid inappro-
priate exclusions?
• Yes: if all people in
whom CFRD was
suspected or screened
were included.
• No: if the above
condition was not met.
• Unclear: if there
was no description of
the inclusion and
exclusion criteria.
Signalling question 3:Did
all participants receive the
same reference standard?
• Yes: if all
participants had
investigations to
diagnose CFRD
according to the ADA
criteria.
• No: if the above
condition is not met.
• Unclear:
insufficient information
available to answer “yes”
or “no”.
Signalling question re-
garding case-control de-
sign has been excluded, as
these studies will be ex-
cluded from the review.
Signalling question 4:
Were all participants in-
cluded in the analysis?
• Yes: if all
participants were
included in the final
statistical analysis.
• No: if the above
condition is not met.
• Unclear:
insufficient information
available to answer “yes”
or “no”.
Risk of bias Could the selection of par-
ticipants have introduced
bias?
• High risk of bias:
at least one question was
scored as ’No’
• Low risk of bias: all
questions were scored
’Yes’, or a maximum of
one question unclear
• Unclear risk of
Could the conduct or in-
terpretation of the index
test have introduced bias?
• High risk of bias:
either of signalling
questions 1 or 2
answered “no”.
• Low risk of bias:
signalling questions 1
and 2 are both answered
“yes”.
Could the reference stan-
dard, its conduct, or its
interpretation have intro-
duced bias?
• Low risk: signalling
questions 1 and 2 are
both answered “yes”.
• High risk: either of
signalling questions 1 or
2 answered “no”
• Unclear risk of
Could
the participant flow have
introduced bias?
• High risk of bias:
at least one question was
scored as ’No’.
• Low risk of bias: all
questions were scored
’Yes’, or a maximum of
one question with
unclear.
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bias: insufficient
information available to
make a judgement
• Unclear risk of
bias: insufficient
information available.
bias: insufficient
information available.
• Unclear risk of
bias: insufficient
information available to
make a judgement.
Applicability Are there concerns that the
included participants and
setting do not match the
review question?
• Low concern: if the
study population meets
the defined criteria
• High concern:
participants as described
above are not included
• Unclear:
insufficient information
available to make a
judgement.
Are there concerns that the
index test, its conduct, or
interpretation differ from
the review question?
• Low concern: if
CGMS was performed
and interpreted
correctly as per the
review question.
• High concern: if
the above condition was
not met.
• Unclear:
insufficient information
available.
Are there concerns that the
target condition as defined
by the reference standard
does not match the ques-
tion?
• Low concern: if the
reference standard was
the ADA criteria and if
the target condition was
suspected CFRD in an
individual as defined in
our protocol.
• High concern: if
the above conditions are
not met.
• Unclear:
insufficient information
available.
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Date Event Description
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run searches Sarah Sutton
select which trials to include (2 + 1 arbiter) Molla Imaduddin Ahmed, Rachel Fox, Erol Gaillard
extract data from trials (2 people) Molla Imaduddin Ahmed, Rachel Fox
enter data into RevMan Molla Imaduddin Ahmed, Rachel Fox
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